

NCIC CLINICAL TRIALS GROUP

LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO

ROOM: CHURCHILL A

SATURDAY APRIL 28^H, 2012

1:30 – 4:30 PM

CHAIRS: G. GOSS / Y. UNG

Objectives:

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with NCIC Clinical Trials Group

1:30 – 1:40 pm	Welcome and Review of the year	G. Goss/Y. Ung
1:40 – 2:15 pm	Plenary Session – Review of Translational Science in Lung Cancer using trial BR.10 as a model	F. Shepherd
2:15 – 2:55 pm	Report from Study Chairs: Update on Current Trials	
	<ul style="list-style-type: none"> • <u>BR.29</u> - A double-blind randomized trial of cediranib vs placebo in patients receiving paclitaxel/carboplatin chemotherapy for the treatment of advanced or metastatic NSCLC. S. Laurie • <u>BR.25</u> - Hypofractionated radiotherapy for medically inoperable NSCLC P. Cheung • <u>IND.196</u> - Phase I/II c-met inhibitor/erlotinib N. Leigh 	
2:55 – 3:05 pm	BREAK	
3:05 – 3:55 pm	<ul style="list-style-type: none"> • <u>BR.26</u> - A double-blind placebo-controlled trial of PF-00299804 (dacomitinib) in advanced NSCLC P. Bradbury • <u>BR.28</u> - CONVERT– Once daily versus twice daily radiation for limited SCLC P. Bradbury • <u>BRC.5</u> - CALGB 140503 A Phase III randomized trial of lobectomy vs sub-lobar resection for small (≤ 2cm) peripheral NSCLC J. Deslauriers • <u>BRC.2</u> - ECOG 1505 Randomized trial of chemotherapy +/- bevacizumab in completely resected Stage IB-IIIa NSCLC N. Leigh • <u>IND.190</u> - Phase I-II trial of etoposide/cisplatin + IGFR1 inhibitor in extensive stage SCLC P. Bradbury • <u>IND.207</u> – Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma P. Wheatley-Price • <u>IND.211</u> - Phase II Study of Reolysin + docetaxel or pemetrexed in advanced NSCLC D. Morris 	
3:55 – 4:15 pm	New Concepts and Proposals	G. Goss/Y. Ung
4.15 – 4:25 pm	Summary and Close	G. Goss/Y. Ung